Click for best price
Antineoplastic Drugs Market Size, Share 2022
Market Analysis and Insights: Global Antineoplastic Drugs Market
The global Antineoplastic Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Antineoplastic Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Antineoplastic Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Antineoplastic Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Antineoplastic Drugs market.
Global Antineoplastic Drugs Scope and Market Size
Antineoplastic Drugs market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Antineoplastic Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Antineoplastic Drugs market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Chemotherapeutic Agents
Biological/Immunotherapeutic Agents
Personalized Medicine
Segment by Application
Hospitals
Clinics
Cancer Rehabilitation Centers
Ambulatory Surgical Centers
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Hoffmann-La Roche
Amgen
Bristol-Myers Squibb
Baxter Healthcare
Boehringer Ingelheim
Aspen Global
Bayer AG
Teva pharmaceutical Industries
Johnson & Johnson
Merc & Co.
Pfize
Accord Healthcare
Genentech
Lundbeck
AbbVie
The information for each competitor/Company Profile includes:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The content of the study subjects includes a total of 15 chapters:
Chapter 1, describes Antineoplastic Drugs product scope, market overview, market opportunities, market driving force, and market risks.
Chapter 2, profiles the top manufacturers of Antineoplastic Drugs, with price, sales, revenue, and global market share of Antineoplastic Drugs from 2019 to 2022.
Chapter 3, the Antineoplastic Drugs competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Antineoplastic Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.
Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Antineoplastic Drugs market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Antineoplastic Drugs.
Chapter 13, 14, and 15, to describe Antineoplastic Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Key Indicators Analysed:
- Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
- Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
- Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
- Opportunities and Drivers: Identifying the Growing Demands and New Technology
- Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Reasons to Purchase this Report:
- Estimates 2022-2027 2021-2025 Antineoplastic Drugs Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
- 1-year analyst support, along with the data support in excel format.
Research Methodology:
The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
| Report Attributes |
Report Details |
| Report Title |
Global and United States Antineoplastic Drugs Market Report & Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
118 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Study Coverage
1.1 Antineoplastic Drugs Product Introduction
1.2 Global Antineoplastic Drugs Outlook 2017 VS 2022 VS 2028
1.2.1 Global Antineoplastic Drugs Sales in US$ Million for the Year 2017-2028
1.2.2 Global Antineoplastic Drugs Sales in Volume for the Year 2017-2028
1.3 United States Antineoplastic Drugs Outlook 2017 VS 2022 VS 2028
1.3.1 United States Antineoplastic Drugs Sales in US$ Million for the Year 2017-2028
1.3.2 United States Antineoplastic Drugs Sales in Volume for the Year 2017-2028
1.4 Antineoplastic Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Antineoplastic Drugs in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Antineoplastic Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Antineoplastic Drugs Market Dynamics
1.5.1 Antineoplastic Drugs Industry Trends
1.5.2 Antineoplastic Drugs Market Drivers
1.5.3 Antineoplastic Drugs Market Challenges
1.5.4 Antineoplastic Drugs Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 Antineoplastic Drugs Market Segment by Type
2.1.1 Chemotherapeutic Agents
2.1.2 Biological/Immunotherapeutic Agents
2.1.3 Personalized Medicine
2.2 Global Antineoplastic Drugs Market Size by Type
2.2.1 Global Antineoplastic Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Antineoplastic Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Antineoplastic Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Antineoplastic Drugs Market Size by Type
2.3.1 United States Antineoplastic Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Antineoplastic Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Antineoplastic Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 Antineoplastic Drugs Market Segment by Application
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Cancer Rehabilitation Centers
3.1.4 Ambulatory Surgical Centers
3.2 Global Antineoplastic Drugs Market Size by Application
3.2.1 Global Antineoplastic Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Antineoplastic Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Antineoplastic Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Antineoplastic Drugs Market Size by Application
3.3.1 United States Antineoplastic Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Antineoplastic Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Antineoplastic Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Antineoplastic Drugs Competitor Landscape by Company
4.1 Global Antineoplastic Drugs Market Size by Company
4.1.1 Top Global Antineoplastic Drugs Manufacturers Ranked by Revenue (2021)
4.1.2 Global Antineoplastic Drugs Revenue by Manufacturer (2017-2022)
4.1.3 Global Antineoplastic Drugs Sales by Manufacturer (2017-2022)
4.1.4 Global Antineoplastic Drugs Price by Manufacturer (2017-2022)
4.2 Global Antineoplastic Drugs Concentration Ratio (CR)
4.2.1 Antineoplastic Drugs Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Antineoplastic Drugs in 2021
4.2.3 Global Antineoplastic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Antineoplastic Drugs Manufacturing Base Distribution, Product Type
4.3.1 Global Antineoplastic Drugs Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Antineoplastic Drugs Product Type
4.3.3 Date of International Manufacturers Enter into Antineoplastic Drugs Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Antineoplastic Drugs Market Size by Company
4.5.1 Top Antineoplastic Drugs Players in United States, Ranked by Revenue (2021)
4.5.2 United States Antineoplastic Drugs Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Antineoplastic Drugs Sales by Players (2020, 2021 & 2022)
5 Global Antineoplastic Drugs Market Size by Region
5.1 Global Antineoplastic Drugs Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Antineoplastic Drugs Market Size in Volume by Region (2017-2028)
5.2.1 Global Antineoplastic Drugs Sales in Volume by Region: 2017-2022
5.2.2 Global Antineoplastic Drugs Sales in Volume Forecast by Region (2023-2028)
5.3 Global Antineoplastic Drugs Market Size in Value by Region (2017-2028)
5.3.1 Global Antineoplastic Drugs Sales in Value by Region: 2017-2022
5.3.2 Global Antineoplastic Drugs Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Antineoplastic Drugs Market Size YoY Growth 2017-2028
6.1.2 North America Antineoplastic Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Antineoplastic Drugs Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Antineoplastic Drugs Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Antineoplastic Drugs Market Size YoY Growth 2017-2028
6.3.2 Europe Antineoplastic Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Antineoplastic Drugs Market Size YoY Growth 2017-2028
6.4.2 Latin America Antineoplastic Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Antineoplastic Drugs Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Antineoplastic Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Hoffmann-La Roche
7.1.1 Hoffmann-La Roche Corporation Information
7.1.2 Hoffmann-La Roche Description and Business Overview
7.1.3 Hoffmann-La Roche Antineoplastic Drugs Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Hoffmann-La Roche Antineoplastic Drugs Products Offered
7.1.5 Hoffmann-La Roche Recent Development
7.2 Amgen
7.2.1 Amgen Corporation Information
7.2.2 Amgen Description and Business Overview
7.2.3 Amgen Antineoplastic Drugs Sales, Revenue and Gross Margin (2017-2022)
7.2.4 Amgen Antineoplastic Drugs Products Offered
7.2.5 Amgen Recent Development
7.3 Bristol-Myers Squibb
7.3.1 Bristol-Myers Squibb Corporation Information
7.3.2 Bristol-Myers Squibb Description and Business Overview
7.3.3 Bristol-Myers Squibb Antineoplastic Drugs Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Bristol-Myers Squibb Antineoplastic Drugs Products Offered
7.3.5 Bristol-Myers Squibb Recent Development
7.4 Baxter Healthcare
7.4.1 Baxter Healthcare Corporation Information
7.4.2 Baxter Healthcare Description and Business Overview
7.4.3 Baxter Healthcare Antineoplastic Drugs Sales, Revenue and Gross Margin (2017-2022)
7.4.4 Baxter Healthcare Antineoplastic Drugs Products Offered
7.4.5 Baxter Healthcare Recent Development
7.5 Boehringer Ingelheim
7.5.1 Boehringer Ingelheim Corporation Information
7.5.2 Boehringer Ingelheim Description and Business Overview
7.5.3 Boehringer Ingelheim Antineoplastic Drugs Sales, Revenue and Gross Margin (2017-2022)
7.5.4 Boehringer Ingelheim Antineoplastic Drugs Products Offered
7.5.5 Boehringer Ingelheim Recent Development
7.6 Aspen Global
7.6.1 Aspen Global Corporation Information
7.6.2 Aspen Global Description and Business Overview
7.6.3 Aspen Global Antineoplastic Drugs Sales, Revenue and Gross Margin (2017-2022)
7.6.4 Aspen Global Antineoplastic Drugs Products Offered
7.6.5 Aspen Global Recent Development
7.7 Bayer AG
7.7.1 Bayer AG Corporation Information
7.7.2 Bayer AG Description and Business Overview
7.7.3 Bayer AG Antineoplastic Drugs Sales, Revenue and Gross Margin (2017-2022)
7.7.4 Bayer AG Antineoplastic Drugs Products Offered
7.7.5 Bayer AG Recent Development
7.8 Teva pharmaceutical Industries
7.8.1 Teva pharmaceutical Industries Corporation Information
7.8.2 Teva pharmaceutical Industries Description and Business Overview
7.8.3 Teva pharmaceutical Industries Antineoplastic Drugs Sales, Revenue and Gross Margin (2017-2022)
7.8.4 Teva pharmaceutical Industries Antineoplastic Drugs Products Offered
7.8.5 Teva pharmaceutical Industries Recent Development
7.9 Johnson & Johnson
7.9.1 Johnson & Johnson Corporation Information
7.9.2 Johnson & Johnson Description and Business Overview
7.9.3 Johnson & Johnson Antineoplastic Drugs Sales, Revenue and Gross Margin (2017-2022)
7.9.4 Johnson & Johnson Antineoplastic Drugs Products Offered
7.9.5 Johnson & Johnson Recent Development
7.10 Merc & Co.
7.10.1 Merc & Co. Corporation Information
7.10.2 Merc & Co. Description and Business Overview
7.10.3 Merc & Co. Antineoplastic Drugs Sales, Revenue and Gross Margin (2017-2022)
7.10.4 Merc & Co. Antineoplastic Drugs Products Offered
7.10.5 Merc & Co. Recent Development
7.11 Pfize
7.11.1 Pfize Corporation Information
7.11.2 Pfize Description and Business Overview
7.11.3 Pfize Antineoplastic Drugs Sales, Revenue and Gross Margin (2017-2022)
7.11.4 Pfize Antineoplastic Drugs Products Offered
7.11.5 Pfize Recent Development
7.12 Accord Healthcare
7.12.1 Accord Healthcare Corporation Information
7.12.2 Accord Healthcare Description and Business Overview
7.12.3 Accord Healthcare Antineoplastic Drugs Sales, Revenue and Gross Margin (2017-2022)
7.12.4 Accord Healthcare Products Offered
7.12.5 Accord Healthcare Recent Development
7.13 Genentech
7.13.1 Genentech Corporation Information
7.13.2 Genentech Description and Business Overview
7.13.3 Genentech Antineoplastic Drugs Sales, Revenue and Gross Margin (2017-2022)
7.13.4 Genentech Products Offered
7.13.5 Genentech Recent Development
7.14 Lundbeck
7.14.1 Lundbeck Corporation Information
7.14.2 Lundbeck Description and Business Overview
7.14.3 Lundbeck Antineoplastic Drugs Sales, Revenue and Gross Margin (2017-2022)
7.14.4 Lundbeck Products Offered
7.14.5 Lundbeck Recent Development
7.15 AbbVie
7.15.1 AbbVie Corporation Information
7.15.2 AbbVie Description and Business Overview
7.15.3 AbbVie Antineoplastic Drugs Sales, Revenue and Gross Margin (2017-2022)
7.15.4 AbbVie Products Offered
7.15.5 AbbVie Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 Antineoplastic Drugs Industry Chain Analysis
8.2 Antineoplastic Drugs Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Antineoplastic Drugs Distributors
8.3 Antineoplastic Drugs Production Mode & Process
8.4 Antineoplastic Drugs Sales and Marketing
8.4.1 Antineoplastic Drugs Sales Channels
8.4.2 Antineoplastic Drugs Distributors
8.5 Antineoplastic Drugs Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Antineoplastic Drugs CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
Table 2. Antineoplastic Drugs Market Trends
Table 3. Antineoplastic Drugs Market Drivers
Table 4. Antineoplastic Drugs Market Challenges
Table 5. Antineoplastic Drugs Market Restraints
Table 6. Global Antineoplastic Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States Antineoplastic Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global Antineoplastic Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States Antineoplastic Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top Antineoplastic Drugs Manufacturers in Global Market, Ranking by Revenue (2021)
Table 11. Global Antineoplastic Drugs Revenue by Manufacturer, (US$ Million), 2017-2022
Table 12. Global Antineoplastic Drugs Revenue Share by Manufacturer, 2017-2022
Table 13. Global Antineoplastic Drugs Sales by Manufacturer, (K Units), 2017-2022
Table 14. Global Antineoplastic Drugs Sales Share by Manufacturer, 2017-2022
Table 15. Global Antineoplastic Drugs Price by Manufacturer (2017-2022) & (USD/Unit)
Table 16. Global Antineoplastic Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Antineoplastic Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antineoplastic Drugs as of 2021)
Table 18. Top Players of Antineoplastic Drugs in Global Market, Headquarters and Distribution of Producing Region
Table 19. Manufacturers Antineoplastic Drugs Product Type
Table 20. Date of International Manufacturers Enter into Antineoplastic Drugs Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Top Antineoplastic Drugs Players in United States Market, Ranking by Revenue (2021)
Table 23. United States Antineoplastic Drugs Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 24. United States Antineoplastic Drugs Revenue Share by Players, 2020, 2021 & 2022
Table 25. United States Antineoplastic Drugs Sales by Players, (K Units), 2020, 2021 & 2022
Table 26. United States Antineoplastic Drugs Sales Share by Players, 2020, 2021 & 2022
Table 27. Global Antineoplastic Drugs Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 28. Global Antineoplastic Drugs Sales in Volume by Region (2017-2022) & (K Units)
Table 29. Global Antineoplastic Drugs Sales in Volume Forecast by Region (2023-2028) & (K Units)
Table 30. Global Antineoplastic Drugs Sales in Value by Region (2017-2022) & (US$ Million)
Table 31. Global Antineoplastic Drugs Sales in Value Forecast by Region (2023-2028) & (US$ Million)
Table 32. North America Antineoplastic Drugs Sales in Volume by Country (2017-2028) & (K Units)
Table 33. North America Antineoplastic Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 34. Asia Pacific Antineoplastic Drugs Sales in Volume by Region (2017-2028) & (K Units)
Table 35. Asia Pacific Antineoplastic Drugs Sales in Value by Region (2017-2028) & (US$ Million)
Table 36. Europe Antineoplastic Drugs Sales in Volume by Country (2017-2028) & (K Units)
Table 37. Europe Antineoplastic Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 38. Latin America Antineoplastic Drugs Sales in Volume by Country (2017-2028) & (K Units)
Table 39. Latin Americaa Antineoplastic Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 40. Middle East and Africa Antineoplastic Drugs Sales in Volume by Country (2017-2028) & (K Units)
Table 41. Middle East and Africa Antineoplastic Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 42. Hoffmann-La Roche Corporation Information
Table 43. Hoffmann-La Roche Description and Business Overview
Table 44. Hoffmann-La Roche Antineoplastic Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 45. Hoffmann-La Roche Antineoplastic Drugs Product
Table 46. Hoffmann-La Roche Recent Development
Table 47. Amgen Corporation Information
Table 48. Amgen Description and Business Overview
Table 49. Amgen Antineoplastic Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 50. Amgen Product
Table 51. Amgen Recent Development
Table 52. Bristol-Myers Squibb Corporation Information
Table 53. Bristol-Myers Squibb Description and Business Overview
Table 54. Bristol-Myers Squibb Antineoplastic Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 55. Bristol-Myers Squibb Product
Table 56. Bristol-Myers Squibb Recent Development
Table 57. Baxter Healthcare Corporation Information
Table 58. Baxter Healthcare Description and Business Overview
Table 59. Baxter Healthcare Antineoplastic Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 60. Baxter Healthcare Product
Table 61. Baxter Healthcare Recent Development
Table 62. Boehringer Ingelheim Corporation Information
Table 63. Boehringer Ingelheim Description and Business Overview
Table 64. Boehringer Ingelheim Antineoplastic Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 65. Boehringer Ingelheim Product
Table 66. Boehringer Ingelheim Recent Development
Table 67. Aspen Global Corporation Information
Table 68. Aspen Global Description and Business Overview
Table 69. Aspen Global Antineoplastic Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 70. Aspen Global Product
Table 71. Aspen Global Recent Development
Table 72. Bayer AG Corporation Information
Table 73. Bayer AG Description and Business Overview
Table 74. Bayer AG Antineoplastic Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 75. Bayer AG Product
Table 76. Bayer AG Recent Development
Table 77. Teva pharmaceutical Industries Corporation Information
Table 78. Teva pharmaceutical Industries Description and Business Overview
Table 79. Teva pharmaceutical Industries Antineoplastic Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 80. Teva pharmaceutical Industries Product
Table 81. Teva pharmaceutical Industries Recent Development
Table 82. Johnson & Johnson Corporation Information
Table 83. Johnson & Johnson Description and Business Overview
Table 84. Johnson & Johnson Antineoplastic Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 85. Johnson & Johnson Product
Table 86. Johnson & Johnson Recent Development
Table 87. Merc & Co. Corporation Information
Table 88. Merc & Co. Description and Business Overview
Table 89. Merc & Co. Antineoplastic Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 90. Merc & Co. Product
Table 91. Merc & Co. Recent Development
Table 92. Pfize Corporation Information
Table 93. Pfize Description and Business Overview
Table 94. Pfize Antineoplastic Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 95. Pfize Product
Table 96. Pfize Recent Development
Table 97. Accord Healthcare Corporation Information
Table 98. Accord Healthcare Description and Business Overview
Table 99. Accord Healthcare Antineoplastic Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 100. Accord Healthcare Product
Table 101. Accord Healthcare Recent Development
Table 102. Genentech Corporation Information
Table 103. Genentech Description and Business Overview
Table 104. Genentech Antineoplastic Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 105. Genentech Product
Table 106. Genentech Recent Development
Table 107. Lundbeck Corporation Information
Table 108. Lundbeck Description and Business Overview
Table 109. Lundbeck Antineoplastic Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 110. Lundbeck Product
Table 111. Lundbeck Recent Development
Table 112. AbbVie Corporation Information
Table 113. AbbVie Description and Business Overview
Table 114. AbbVie Antineoplastic Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 115. AbbVie Product
Table 116. AbbVie Recent Development
Table 117. Key Raw Materials Lists
Table 118. Raw Materials Key Suppliers Lists
Table 119. Antineoplastic Drugs Customers List
Table 120. Antineoplastic Drugs Distributors List
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
List of Figures
Figure 1. Antineoplastic Drugs Product Picture
Figure 2. Global Antineoplastic Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global Antineoplastic Drugs Market Size 2017-2028 (US$ Million)
Figure 4. Global Antineoplastic Drugs Sales 2017-2028 (K Units)
Figure 5. United States Antineoplastic Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 6. United States Antineoplastic Drugs Market Size 2017-2028 (US$ Million)
Figure 7. United States Antineoplastic Drugs Sales 2017-2028 (K Units)
Figure 8. United States Antineoplastic Drugs Market Share in Global, in Value (US$ Million) 2017-2028
Figure 9. United States Antineoplastic Drugs Market Share in Global, in Volume (K Units) 2017-2028
Figure 10. Antineoplastic Drugs Report Years Considered
Figure 11. Product Picture of Chemotherapeutic Agents
Figure 12. Product Picture of Biological/Immunotherapeutic Agents
Figure 13. Product Picture of Personalized Medicine
Figure 14. Global Antineoplastic Drugs Market Share by Type in 2022 & 2028
Figure 15. Global Antineoplastic Drugs Sales in Value by Type (2017-2028) & (US$ Million)
Figure 16. Global Antineoplastic Drugs Sales Market Share in Value by Type (2017-2028)
Figure 17. Global Antineoplastic Drugs Sales by Type (2017-2028) & (K Units)
Figure 18. Global Antineoplastic Drugs Sales Market Share in Volume by Type (2017-2028)
Figure 19. Global Antineoplastic Drugs Price by Type (2017-2028) & (USD/Unit)
Figure 20. United States Antineoplastic Drugs Market Share by Type in 2022 & 2028
Figure 21. United States Antineoplastic Drugs Sales in Value by Type (2017-2028) & (US$ Million)
Figure 22. United States Antineoplastic Drugs Sales Market Share in Value by Type (2017-2028)
Figure 23. United States Antineoplastic Drugs Sales by Type (2017-2028) & (K Units)
Figure 24. United States Antineoplastic Drugs Sales Market Share in Volume by Type (2017-2028)
Figure 25. United States Antineoplastic Drugs Price by Type (2017-2028) & (USD/Unit)
Figure 26. Product Picture of Hospitals
Figure 27. Product Picture of Clinics
Figure 28. Product Picture of Cancer Rehabilitation Centers
Figure 29. Product Picture of Ambulatory Surgical Centers
Figure 30. Global Antineoplastic Drugs Market Share by Application in 2022 & 2028
Figure 31. Global Antineoplastic Drugs Sales in Value by Application (2017-2028) & (US$ Million)
Figure 32. Global Antineoplastic Drugs Sales Market Share in Value by Application (2017-2028)
Figure 33. Global Antineoplastic Drugs Sales by Application (2017-2028) & (K Units)
Figure 34. Global Antineoplastic Drugs Sales Market Share in Volume by Application (2017-2028)
Figure 35. Global Antineoplastic Drugs Price by Application (2017-2028) & (USD/Unit)
Figure 36. United States Antineoplastic Drugs Market Share by Application in 2022 & 2028
Figure 37. United States Antineoplastic Drugs Sales in Value by Application (2017-2028) & (US$ Million)
Figure 38. United States Antineoplastic Drugs Sales Market Share in Value by Application (2017-2028)
Figure 39. United States Antineoplastic Drugs Sales by Application (2017-2028) & (K Units)
Figure 40. United States Antineoplastic Drugs Sales Market Share in Volume by Application (2017-2028)
Figure 41. United States Antineoplastic Drugs Price by Application (2017-2028) & (USD/Unit)
Figure 42. North America Antineoplastic Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 43. North America Antineoplastic Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 44. U.S. Antineoplastic Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 45. Canada Antineoplastic Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 46. Europe Antineoplastic Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 47. Europe Antineoplastic Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 48. Germany Antineoplastic Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 49. France Antineoplastic Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 50. U.K. Antineoplastic Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 51. Italy Antineoplastic Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 52. Russia Antineoplastic Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 53. Asia-Pacific Antineoplastic Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 54. Asia-Pacific Antineoplastic Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 55. China Antineoplastic Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 56. Japan Antineoplastic Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 57. South Korea Antineoplastic Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 58. India Antineoplastic Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 59. Australia Antineoplastic Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 60. Taiwan Antineoplastic Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 61. Indonesia Antineoplastic Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 62. Thailand Antineoplastic Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 63. Malaysia Antineoplastic Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 64. Philippines Antineoplastic Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 65. Latin America Antineoplastic Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 66. Latin America Antineoplastic Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 67. Mexico Antineoplastic Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 68. Brazil Antineoplastic Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 69. Argentina Antineoplastic Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 70. Middle East & Africa Antineoplastic Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 71. Middle East & Africa Antineoplastic Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 72. Turkey Antineoplastic Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 73. Saudi Arabia Antineoplastic Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 74. U.A.E Antineoplastic Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 75. Antineoplastic Drugs Value Chain
Figure 76. Antineoplastic Drugs Production Process
Figure 77. Channels of Distribution
Figure 78. Distributors Profiles
Figure 79. Bottom-up and Top-down Approaches for This Report
Figure 80. Data Triangulation
Figure 81. Key Executives Interviewed
